{"title":"慢性髓系白血病进展为急性混合系白血病:一个由严重并发症引起的诊断挑战。","authors":"Xu Jing, Luo Shi, Guo Lifu","doi":"10.7754/Clin.Lab.2024.241026","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Chronic myeloid leukemia (CML) is a myeloproliferative disorder that can progress to an accelerated or blast phase if left untreated or inadequately managed. Acute transformation of CML, particularly into mixed lineage leukemia, is a rare and challenging complication. This case report describes the clinical course of a 30-year-old male patient with CML progressing to acute mixed lineage leukemia and complicated by gastrointestinal bleeding.</p><p><strong>Methods: </strong>The patient, initially diagnosed with CML in June 2019, was treated with imatinib. However, after discontinuing treatment on his own, the disease progressed to acute myeloid leukemia (AML-M2a) by June 2020, confirmed by bone marrow analysis, flow cytometry, and cytogenetics showing BCR-ABL1 positivity. Despite multiple chemotherapy regimens, including VCLP, VDP with dasatinib, and COP with dasatinib, the patient's condition failed to improve. He developed recurrent gastrointestinal bleeding, which was managed with acid suppression, blood transfusions, and infection control measures.</p><p><strong>Results: </strong>The patient experienced persistent bone marrow failure, characterized by blasts in peripheral blood and bone marrow, as well as refractory gastrointestinal bleeding despite supportive care. During chemotherapy, the patient also developed severe infections and psychiatric symptoms, complicating the treatment course.</p><p><strong>Conclusions: </strong>This case highlights the aggressive progression of CML to acute mixed lineage leukemia and underscores the challenges in managing patients with resistant disease. The patient's gastrointestinal bleeding and recurrent infections further complicated treatment, emphasizing the need for early intervention and close monitoring of high-risk CML patients.</p>","PeriodicalId":10384,"journal":{"name":"Clinical laboratory","volume":"71 4","pages":""},"PeriodicalIF":0.7000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Chronic Myeloid Leukemia Progression to Acute Mixed-Lineage Leukemia: a Diagnostic Challenge Complicated by Severe Complications.\",\"authors\":\"Xu Jing, Luo Shi, Guo Lifu\",\"doi\":\"10.7754/Clin.Lab.2024.241026\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Chronic myeloid leukemia (CML) is a myeloproliferative disorder that can progress to an accelerated or blast phase if left untreated or inadequately managed. Acute transformation of CML, particularly into mixed lineage leukemia, is a rare and challenging complication. This case report describes the clinical course of a 30-year-old male patient with CML progressing to acute mixed lineage leukemia and complicated by gastrointestinal bleeding.</p><p><strong>Methods: </strong>The patient, initially diagnosed with CML in June 2019, was treated with imatinib. However, after discontinuing treatment on his own, the disease progressed to acute myeloid leukemia (AML-M2a) by June 2020, confirmed by bone marrow analysis, flow cytometry, and cytogenetics showing BCR-ABL1 positivity. Despite multiple chemotherapy regimens, including VCLP, VDP with dasatinib, and COP with dasatinib, the patient's condition failed to improve. He developed recurrent gastrointestinal bleeding, which was managed with acid suppression, blood transfusions, and infection control measures.</p><p><strong>Results: </strong>The patient experienced persistent bone marrow failure, characterized by blasts in peripheral blood and bone marrow, as well as refractory gastrointestinal bleeding despite supportive care. During chemotherapy, the patient also developed severe infections and psychiatric symptoms, complicating the treatment course.</p><p><strong>Conclusions: </strong>This case highlights the aggressive progression of CML to acute mixed lineage leukemia and underscores the challenges in managing patients with resistant disease. The patient's gastrointestinal bleeding and recurrent infections further complicated treatment, emphasizing the need for early intervention and close monitoring of high-risk CML patients.</p>\",\"PeriodicalId\":10384,\"journal\":{\"name\":\"Clinical laboratory\",\"volume\":\"71 4\",\"pages\":\"\"},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical laboratory\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.7754/Clin.Lab.2024.241026\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"MEDICAL LABORATORY TECHNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical laboratory","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.7754/Clin.Lab.2024.241026","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
Chronic Myeloid Leukemia Progression to Acute Mixed-Lineage Leukemia: a Diagnostic Challenge Complicated by Severe Complications.
Background: Chronic myeloid leukemia (CML) is a myeloproliferative disorder that can progress to an accelerated or blast phase if left untreated or inadequately managed. Acute transformation of CML, particularly into mixed lineage leukemia, is a rare and challenging complication. This case report describes the clinical course of a 30-year-old male patient with CML progressing to acute mixed lineage leukemia and complicated by gastrointestinal bleeding.
Methods: The patient, initially diagnosed with CML in June 2019, was treated with imatinib. However, after discontinuing treatment on his own, the disease progressed to acute myeloid leukemia (AML-M2a) by June 2020, confirmed by bone marrow analysis, flow cytometry, and cytogenetics showing BCR-ABL1 positivity. Despite multiple chemotherapy regimens, including VCLP, VDP with dasatinib, and COP with dasatinib, the patient's condition failed to improve. He developed recurrent gastrointestinal bleeding, which was managed with acid suppression, blood transfusions, and infection control measures.
Results: The patient experienced persistent bone marrow failure, characterized by blasts in peripheral blood and bone marrow, as well as refractory gastrointestinal bleeding despite supportive care. During chemotherapy, the patient also developed severe infections and psychiatric symptoms, complicating the treatment course.
Conclusions: This case highlights the aggressive progression of CML to acute mixed lineage leukemia and underscores the challenges in managing patients with resistant disease. The patient's gastrointestinal bleeding and recurrent infections further complicated treatment, emphasizing the need for early intervention and close monitoring of high-risk CML patients.
期刊介绍:
Clinical Laboratory is an international fully peer-reviewed journal covering all aspects of laboratory medicine and transfusion medicine. In addition to transfusion medicine topics Clinical Laboratory represents submissions concerning tissue transplantation and hematopoietic, cellular and gene therapies. The journal publishes original articles, review articles, posters, short reports, case studies and letters to the editor dealing with 1) the scientific background, implementation and diagnostic significance of laboratory methods employed in hospitals, blood banks and physicians'' offices and with 2) scientific, administrative and clinical aspects of transfusion medicine and 3) in addition to transfusion medicine topics Clinical Laboratory represents submissions concerning tissue transplantation and hematopoietic, cellular and gene therapies.